Inclusion Criteria:  Meet the diagnostic criteria of Guillain - Barre syndrome; The onset is within 2 weeks; Age is greater than or equal to 18 years old and less than or equal to 60 years old; Hughes function classification is greater than or equal to 3; The subject or his legal representative can understand the purpose of the research, show sufficient compliance with the research protocol, and sign an informed consent form.  Exclusion Criteria:  Those who are pregnant; Three months before the screening period, receive immunoadsorption therapy or intravenous immunoglobulin therapy; Those who have a history of allergies in the membrane of the plasma separator; Those who must use angiotensin-converting enzyme inhibitor drugs within 1 week before being included in the trial and during treatment and cannot be stopped; Severe active bleeding or diffuse intravascular coagulation, patients with systemic circulatory failure that are difficult to correct with drugs; Severe cardiac insufficiency, that is, those who have reached NYHA IV according to the heart failure classification standards of the New York Heart Association (NYHA); There are contraindications to intravenous immunoglobulin; Those with other system autoimmune diseases; Diagnosis of variant GBS: such as Miller-Fisher syndrome, GBS with cranial nerve damage, sensory GBS, pan-autonomous GBS. Patients with chronic inflammatory demyelinating polyperipheral neuropathy whose condition has been significantly alleviated when visiting a doctor; Subjects who have participated in any other drug or medical device clinical trials within 1 month before entering the screening period; Note: Subjects who participated in observational studies (that is, the study does not require changes or other interventions) will not be excluded; Patients who cannot obtain informed consent; Those who cannot receive active and comprehensive treatment.